Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Zentalis Pharmaceuticals Inc | ZNTL | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 11.11 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 11.11 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 9.56 - 31.46 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 11.11 | USD |
Zentalis Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 788.37M | 70.96M | - | 0 | -292.19M | -4.12 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Zentalis Pharmaceuticals News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ZNTL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.10 | 12.00 | 10.77 | 11.20 | 676,658 | 0.01 | 0.09% |
| 1 Month | 15.14 | 15.79 | 10.39 | 12.74 | 710,054 | -4.03 | -26.62% |
| 3 Months | 11.71 | 18.07 | 10.39 | 13.76 | 830,308 | -0.60 | -5.12% |
| 6 Months | 16.90 | 18.24 | 9.56 | 13.03 | 955,128 | -5.79 | -34.26% |
| 1 Year | 21.44 | 31.46 | 9.56 | 18.23 | 882,249 | -10.33 | -48.18% |
| 3 Years | 60.02 | 87.19 | 9.56 | 26.62 | 621,303 | -48.91 | -81.49% |
| 5 Years | 24.69 | 87.19 | 9.56 | 28.85 | 523,043 | -13.58 | -55.00% |
Zentalis Pharmaceuticals Description
| Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. |
